Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori.

Slomiany BL, Piotrowski J, Mojtahed H, Slomiany A.

Gen Pharmacol. 1992 Mar;23(2):203-6.

PMID:
1639232
2.

Sulglycotide effect on the proteolytic and lipolytic activities of Helicobacter pylori toward gastric mucus.

Piotrowski J, Czajkowski A, Yotsumoto F, Slomiany A, Slomiany BL.

Am J Gastroenterol. 1994 Feb;89(2):232-6.

PMID:
8304309
3.

Effect of sucralfate on the degradation of human gastric mucus by Helicobacter pylori protease and lipases.

Slomiany BL, Piotrowski J, Slomiany A.

Am J Gastroenterol. 1992 May;87(5):595-9.

PMID:
1595646
4.

Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.

Slomiany BL, Piotrowski J, Slomiany A.

Arzneimittelforschung. 1997 Apr;47(4A):475-82. Review.

PMID:
9205747
5.

Susceptibility of growth factors to degradation by Helicobacter pylori protease: effect of ebrotidine and sucralfate.

Slomiany BL, Piotrowski J, Slomiany A.

Biochem Mol Biol Int. 1996 Sep;40(1):209-15.

PMID:
8886287
6.

Inhibition of Helicobacter pylori urease activity by ebrotidine.

Piotrowski J, Slomiany A, Slomiany BL.

Biochem Mol Biol Int. 1995 Oct;37(2):247-53.

PMID:
8673007
7.

Inhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: effect of ebrotidine.

Slomiany BL, Piotrowski J, Murty VL, Slomiany A.

Gen Pharmacol. 1995 Nov;26(7):1553-8.

PMID:
8690245
8.

Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.

Slomiany BL, Piotrowski J, Slomiany A.

J Physiol Pharmacol. 1999 Sep;50(3):391-404.

PMID:
10574469
9.

Helicobacter pylori aggregating activity of gastric mucin with ulcer healing by ebrotidine.

Piotrowski J, Majka J, Piotrowski E, Murty VL, Gabryelewicz A, Slomiany A, Slomiany BL.

Biochem Mol Biol Int. 1994 Nov;34(5):875-81.

PMID:
7535617
10.

Enhancement in the protective qualities of gastric mucus with combination therapy of ebrotidine and amoxicillin for H. pylori eradication.

Slomiany BL, Piotrowski J, Slomiany A, Konturek JW, Domschke WW.

Gen Pharmacol. 1998 Aug;31(2):227-31.

PMID:
9688464
11.

Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.

Slomiany BL, Piotrowski J, Majka J, Czajkowski A, Slomiany A, Gabryelewicz A.

Gen Pharmacol. 1995 Sep;26(5):1039-44.

PMID:
7557247
12.

Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide.

Piotrowski J, Skrodzka D, Slomiany A, Slomiany BL.

Gen Pharmacol. 1997 May;28(5):705-8.

PMID:
9184806
13.

Effect of ebrotidine on the synthesis and secretion of gastric sulfomucin.

Slomiany BL, Lopez RA, Liau YH, Slomiany A.

Gen Pharmacol. 1993 May;24(3):611-7.

PMID:
8365641
14.

Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of ebrotidine.

Piotrowski J, Morita M, Slomiany A, Slomiany BL.

Biochem Int. 1992 Jun;27(1):131-8.

PMID:
1385705
15.

Ebrotidine.

Patel SS, Wilde MI.

Drugs. 1996 Jun;51(6):974-80; discussion 981. Review.

PMID:
8736619
16.

Synthesis and secretion of gastric sulfomucin in the presence of ebrotidine, a new antiulcer agent.

Slomiany BL, Lopez RA, Slomiany A.

Biochem Int. 1992 Dec;28(4):665-74.

PMID:
1482403
17.

Gastroprotective agents in mucosal defense against Helicobacter pylori.

Slomiany BL, Murty VL, Piotrowski J, Slomiany A.

Gen Pharmacol. 1994 Sep;25(5):833-41. Review.

PMID:
7835626
18.

Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine.

Slomiany BL, Piotrowski E, Piotrowski J, Zirvi KA, Liau YH, Murty VL, Slomiany A.

Gen Pharmacol. 1994 Sep;25(5):1033-7.

PMID:
7835621
19.

In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori.

Alarcón T, Domingo D, Sánchez I, Sanz JC, Martínez MJ, López-Brea M.

Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):275-7.

PMID:
9707312
20.

Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol)

Slomiany BL, Kasinathan C, Slomiany A.

Am J Gastroenterol. 1989 Oct;84(10):1273-7.

PMID:
2801678

Supplemental Content

Support Center